Bioavailability augmentation of silymarin using natural bioenhancers
An in vivo pharmacokinetic study
DOI:
https://doi.org/10.1590/s2175-97902022e20160Keywords:
Silymarin, Bioavailability, Piperine, Fulvic acid, LysergolAbstract
Pharmacokinetic studies were carried out in male and female rats to quantify silymarin as silybin (A+B) after the oral administration of various silymarin formulations combined with three bioenhancers, namely, lysergol, piperine, and fulvic acid, and compared with plain silymarin formulation (control). A non-compartmental analysis, model independent analysis, was utilized, and various pharmacokinetic parameters (C max, T max, and AUC 0-t) were calculated individually for each treatment group, and the values were expressed as mean ± SEM (n = 6). Plasma samples obtained from the rats were analyzed for the concentration of silymarin through a validated RP-HPLC method and on the basis of data generated from the pharmacokinetic studies. Results indicated that the bioenhancers augmented pharmacokinetic parameters and bioavailability increased 2.4-14.5-fold in all the formulations compared with the control. The current work envisages the development of an industrially viable product that can be further subjected to clinical trials and scientifically supports the development of silymarin as a contemporary therapeutic agent with enhanced bioavailability and medicinal values.
Downloads
References
Atal CK, Dubey RK, Singh J. Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. J Pharmacol Exp Ther. 1985;232(1):258-62.
Badmaev V, Majeed M, Prakash L. Piperine derived from black pepper increases the plasma levels of coenzyme Q10 following oral supplemention. J Nutr Biochem. 2000;11(2):109-13.
Dyke DCV, Nielson AS, Sutton B, Davies D, Adams LB. Method for producing fulvic acid. United States Patent No. US20120279266A1, 2014.
Ferrari G. Method for the extraction of lysergol and ergot alkaloids from plants of the Ipomoea genus, United States Patent No. 3920663, 1975.
Ghosal S. Delivery system for pharmaceutical, nutritional and cosmetic ingredients. United States Patent No. 6558712, 2003.
Jancova P, Anzenbacherova E, Papouskova B, Lemr K, Luzna P, Veinlichova A. Silybin is metabolized by CP450 2C8 in vitro. Drug Metab Dispos. 2007;35(11):2035-39.
Javed S, Ahsan W, Kohli, K. Pharmacological influences of natural products as bioenhancers of silymarin against carbon tetrachloride-induced hepatotoxicity in rats. Clin Phytosci. 2018;4:1-9.
Javed S, Kohli K, Ahsan W. Enhanced intestinal permeability of silymarin by natural products as bioenhancers - Assessment by ex-vivo non-everted rat gut sac study. Bioeq Bioavail Int J. 2018;2(1):000120.
Javed S, Kohli K, Ahsan W. Solubility and dissolution enhancement of silymarin with fulvic acid carrier. Int J Drug Dev Res. 2016;8(1):9-14.
Javed S, Kohli K, Ali M. Reassessing bioavailability of silymarin. Altern Med Rev. 2010a;16(3):239-49.
Javed S, Kohli K, Ali M. Microwave-assisted extraction of fulvic acid from a solid dosage form: A statistical approach. J Pharm Innov. 2013;8:175-86.
Javed S, Kohli K, Ali M. Patented bioavailability enhancement techniques of silymarin. Recent Pat Drug Deliv Formul. 2010b;4(2):145-52.
Khanuja SPS, Arya JS, Srivastava SK. Antibiotic pharmaceutical composition with lysergol as bioenhancer and method of treatment. United States Patent No. 20070060604A1, 2007.
Kren V, Walterova D. Silybin and silymarin - New effects and applications. Biomed Pap 2005;149(1):29-41.
Lorenz D, Lucker PW, Mennicke WH, Wetzelsberger N. Pharmacokinetics studies with silymarin in human serum and bile. Methods Find Exp Clin Pharmacol. 1984;6(10):655-61.
Morazzoni P, Montalbetti A, Malandrino S, Pifferi G. Comparative pharmacokinetics of silipide and silymarin in rats. Eur J Drug Metab Pharmacokinet. 1993;18(3):289-97.
Najar IA, Sharma SC, Singh GD, Koul S, Gupta PN, Javed S, Johri RK. Involvement of P-glycoprotein and CYP3A4 in the enhancement of etoposide bioavailability by a piperine analogue. Chem -Biol Interact. 2011;190(2-3):84-90.
Patil S, Dash RP, Anandjiwala S, Nivsarkar M. Simultaneous quantification of berberine and lysergol by HPLC-UV: evidence that lysergol enhances the oral bioavailability of berberine in rats. Biomed Chromatogr. 2012;26(10):1170-5.
Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 2006;124(5):491-504.
Radko L, Cybulski W. Application of silymarin in human and animal medicine. J Pre-Clin Clin Res. 2007;1(1):22-6.
Sachin BS, Najar IA, Sharma SC, Verma MK, Reddy MV, Anand R, et al. Simultaneous determination of etoposide and piperine analoque (PA-1) by UPLC-qTOF-MS: Evidence that PA-1 enhances the oral bioavailability of etoposide in mice. J Chromatogr B. 2010;878(9-10):823-30.
Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, Smith PC. Pharmacokinetics and metabolic profiles of free, conjugated and total silymarin flavonolignans in human plasma after oral Administration of milk thistle extract. Drug Metab Dispos . 2008;36(1):65-72.
Woo JS, Kim TS, Park JH, Chi SC. Formulation and biopharmaceutical evaluation of silymarin using SMEDDS. Arch Pharm Res. 2007;30(1):82-9.
Wu JW, Lin LC, Hung SC, Lin CH, Chi CW, Tsai TH. Hepatobiliary excretion of silibinin in normal and liver cirrhotic rats. Drug Metab Disp. 2008;36(3):589-96.
Wu JY, Lin LC, Hung SC, Chi CW, Tsai TH. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. J Pharm Biomed Anal. 2007;45(4):635-41.
Yanyu X, Yunmei S, Zhipeng C, Quieng P. The preparation of silybin-phospholipids complex and study on its pharmacokinetics in rats. Int J Pharm. 2006;307(1):77-82.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
How to Cite
Funding data
-
Indian Council of Medical Research
Grant numbers 45/33/009-PHA/BMS
